Lamda out-licensing agreements

Quantum Pharma Plc

("Quantum" or the "Group")

Lamda out-licensing agreements

Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a further three out-licensing deals in Germany, though Lamda (UK) Limited, Lamda Laboratories SA and Lamda Pharmaceuticals SA (collectively 'Lamda'), part of its Niche Pharmaceutical division. These agreements form part of the core strategy for this division.

Under the three licensing, royalty and supply agreements, Lamda will out-license two generic plus and one generic dossiers which Lamda developed. The total fixed licensing fee from these three agreements will be, in aggregate, €375,000 of which €280,000 is payable prior to 31 January 2016. The balance will be payable during late 2016 or early 2017.

Once the products receive a marketing authorisation in Germany Lamda will procure the supply of the manufactured product to the pharmaceutical company for an initial period of five years. This supply agreement is expected to contribute positive margin to the Group from late 2016.

Furthermore, Lamda anticipates that that the launch of these products in Germany, in particular the generic-plus product, will attract interest in other EU markets, leading to increased revenues for the Group.

Andrew Scaife, CEO of Quantum Pharma, said: "As well as providing a number of products in the Niche Pharmaceutical pipeline and in house development for our pipeline Lamda continues to build strategic partnerships with pharmaceutical companies in Europe through its sustained commercialisation of the latent value in its 100+ completed development projects and also through new product development agreements for third parties. Through these deals and the associated supply agreements, Lamda continues to build a sustainable and profitable revenue stream which we expect will continue to grow over the coming years.

"The Niche Pharmaceutical division continues to make good progress as the front end of our product pipeline comes to market and we continue to grow our pipeline and execute further out-licensing agreements into new geographical markets."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials:

Comprising four business units which manufacture, source and supply specials to pharmacies, pharmaceutical wholesalers, hospitals (NHS and private) and other specials suppliers throughout the UK and overseas.

Quantum Pharmaceutical manufactures and supplies specials and special obtains to pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

UL Medicines sources and supplies unlicensed imported medicines, batch made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development and clinical trials product manufacture.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches for supply to private and NHS hospitals and homecare patients.

Niche Pharmaceutical:

Comprising three business units which develop and supply niche pharmaceuticals, provide development and regulatory services and out-license products and dossiers to 3rd parties across Europe.

Colonis is a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda is a full service contract development specialist with customers across Europe. It specialises in creating added value products with distinct advantages for patients and health care providers, providing full services for the entire development chain - from inception to registration, to post approval finished product supply and regulatory support.

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

Medication Adherence:

Comprising two business units which provide products and services designed to enhance adherence to medication regimes:

Protomed which owns Biodose® a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. A telehealth version with the ability to remotely monitor medication adherence is in live testing.

Biodose Services assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

For further information, please visit www.quantumpharmagroup.com.